文献速递淋巴瘤

合并惰性淋巴瘤对新诊断弥漫大B细胞淋巴瘤临床结局的影响

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.
PubMed 文献 · Blood · 2019-01-01

研究基于1324例接受免疫化疗的新诊断DLBCL患者的前瞻性随访队列,分析合并惰性淋巴瘤的患病率、特征及结局。合并FL者以GCB亚型为主,校正IPI后EFS和OS与单纯DLBCL相似;合并其他惰性淋巴瘤者分期较晚,但结局与单纯DLBCL相似。

要点

  • 合并FL的DLBCL患者以GCB亚型为主,校正IPI后EFS(HR=0.95)与单纯DLBCL相似。
  • 合并FL者OS有优于单纯DLBCL的趋势(HR=0.75),但与单纯GCB DLBCL几乎相同(HR=0.84)。
  • 合并其他惰性淋巴瘤者III-IV期更多,EFS(HR=1.19)和OS(HR=1.09)与单纯DLBCL相似。

核心结论

  • 合并FL的DLBCL患者以GCB亚型为主,结局与GCB DLBCL患者相似。
  • 合并其他惰性淋巴瘤的DLBCL患者结局与单纯DLBCL患者相似。
  • 这些患者不应被一概排除在DLBCL临床试验之外。

研究设计与样本

  • 前瞻性随访队列,纳入1324例接受免疫化疗的新诊断DLBCL患者。

主要发现

  • 合并FL者(n=109;8.2%)较单纯DLBCL者(n=1153;87.1%)LDH升高较少、IPI较低、以GCB亚型为主。
  • 合并其他惰性淋巴瘤者(n=62;4.7%)III-IV期疾病更多,IPI较高和非GCB亚型呈趋势。
  • 校正IPI后,合并FL者较单纯DLBCL者EFS的HR=0.95,OS的HR=0.75(趋势);较单纯GCB DLBCL者EFS的HR=1.00,OS的HR=0.84。
  • 合并其他惰性淋巴瘤者较单纯DLBCL者EFS的HR=1.19,OS的HR=1.09。

临床怎么用

  • 合并FL的DLBCL患者预后与GCB DLBCL相似,合并其他惰性淋巴瘤者预后与单纯DLBCL相似,不应一概排除在DLBCL临床试验之外。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Some patients with diffuse large B-cell lymphoma (DLBCL) present with a concurrent indolent lymphoma at diagnosis. Their outcomes in the rituximab era are not fully defined. Using a prospectively followed cohort of 1324 newly diagnosed DLBCL patients treated with immunochemotherapy, we defined the prevalence, characteristics, and outcome of DLBCL with concurrent indolent lymphoma. Compared with patients with DLBCL alone (n = 1153; 87.1%), patients with concurrent DLBCL and follicular lymphoma (FL) (n = 109; 8.2%) had fewer elevations in lactate dehydrogenase, lower International Prognostic Index (IPI), and predominantly germinal center B-cell-like (GCB) subtype, whereas patients with concurrent DLBCL and other indolent lymphomas (n = 62; 4.7%) had more stage III-IV disease and a trend toward higher IPI and non-GCB subtype. After adjusting for IPI, patients with concurrent DLBCL and FL had similar event-free survival (EFS) (hazard ratio [HR] = 0.95) and a trend of better overall survival (OS) (HR = 0.75) compared with patients with DLBCL alone, but nearly identical EFS (HR = 1.00) and OS (HR = 0.84) compared with patients with GCB DLBCL alone. Patients with concurrent DLBCL and other indolent lymphomas had similar EFS (HR = 1.19) and OS (HR = 1.09) compared with patients with DLBCL alone. In conclusion, DLBCL patients with concurrent FL predominantly had the GCB subtype with outcomes similar to that of GCB DLBCL patients. DLBCL patients with concurrent other indolent lymphoma had similar outcomes compared with patients with DLBCL alone. These patients should not be summarily excluded from DLBCL clinical trials.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wang Y, Link BK, Witzig TE, et al. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 2019. PMID: 31350266. doi:10.1182/blood.2019000858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。